Degradation of extracellular and membrane proteins in targeted therapy: Status quo and quo vadis
- 17 July 2023
- journal article
- review article
- Published by Elsevier in Drug Discovery Today
- Vol. 28 (9) , 103716
Abstract
No abstract availableKeywords
This publication has 84 references indexed in Scilit:
- A shortcut to the lysosome: The mannose-6-phosphate-independent pathwayMolecular Genetics and Metabolism, 2012
- Aptamers evolved from live cells as effective molecular probes for cancer studyProceedings of the National Academy of Sciences, 2006
- Off-target effects by siRNA can induce toxic phenotypeRNA, 2006
- Antibody Pharmacokinetics and PharmacodynamicsJournal of Pharmaceutical Sciences, 2004
- Molecular mechanisms of glioma invasiveness: the role of proteasesNature Reviews Cancer, 2003
- Expression profiling reveals off-target gene regulation by RNAiNature Biotechnology, 2003
- ‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerizationProtein Engineering, Design and Selection, 1996
- Endocytosis of interleukin 2 receptors in human T lymphocytes: distinct intracellular localization and fate of the receptor alpha, beta, and gamma chains.Journal of Cell Biology, 1995
- In vitro selection of RNA molecules that bind specific ligandsNature, 1990
- Systematic Evolution of Ligands by Exponential Enrichment: RNA Ligands to Bacteriophage T4 DNA PolymeraseScience, 1990